24/7 Market News Snapshot 30 May, 2025 – PLUS THERAPEUTICS, Inc. Common Stock (NASDAQ:PSTV)

May 30, 2025

DENVER, Colo., 30 May, 2025 (www.247marketnews.com) – (Nasdaq:PSTV) are discussed in this article.
Plus Therapeutics, Inc. (Nasdaq:PSTV) has captured significant market attention with its impressive performance, marked by a notable opening at $0.286 and a remarkable surge of 43.16%, reaching $0.410, backed by a trading volume of 7.50 million shares. This robust upward movement indicates a rising investor interest, potentially fueled by recent advancements and positive developments surrounding the company’s innovative therapies.

In its first-quarter report for the period ending March 31, 2025, Plus Therapeutics outlined substantial progress in both clinical and financial domains. CEO Marc H. Hedrick, M.D., highlighted an enhanced cash position resulting from a recent $15 million private placement and a $2 million grant from the Cancer Prevention and Research Institute. This influx of capital positions the company favorably to advance critical initiatives, particularly the enrollment of patients in ongoing trials for its REYOBIQ™ therapy targeting CNS cancers, and the forthcoming launch of the CNSide® cerebral spinal fluid (CSF) assay platform.

The company has also made strides in clinical research, presenting interim data on REYOBIQ™ at a leading conference, showcasing safety and significant clinical benefits for patients with leptomeningeal metastases. Notably, the results from a Phase 1 trial published in Nature Communications indicate that the therapy has median overall survival rates surpassing conventional treatments for recurrent glioblastoma, highlighting its transformative potential.

Additionally, strategic leadership enhancements, including the appointment of Kyle Guse to the board and Dr. Michael Rosol as Chief Development Officer, bolster the company’s capabilities in clinical development and commercialization. By March 31, 2025, Plus Therapeutics reported a cash balance of $9.9 million, reinforcing its commitment to the research and development of cutting-edge radiotherapeutics.

Looking ahead, the anticipated commercialization of the CNSide™ CSF assay platform in the US in 2025 further solidifies Plus Therapeutics’ position as a leader in innovative cancer diagnostics, aligning with its mission to improve patient outcomes in tackling complex CNS cancers.

Related news for (PSTV)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.